On Thursday shares of Epizyme, Inc. (NASDAQ:EPZM) closed at $18.24. Epizyme, Inc. (NASDAQ:EPZM) on March 18, 2015, released that data from its preclinical pipeline will be presented during the American Association for Cancer Research (AACR) Annual Meeting, to be held April 18-25 in Philadelphia, Pa.
Verint Systems Inc. (NASDAQ:VRNT) in last trading activity moved up 6.16% to close at $62.23. Company weekly performance is 1.02% while its quarterly performance stands at 5.47%. Verint Systems Inc. (NASDAQ:VRNT) is -0.14% away from its 52 week high. Verint Systems Inc. (NASDAQ:VRNT) announced that it will host an investor day on Tuesday, June 9, 2015 in Las Vegas. The event will take place at the same venue as the company’s Engage™ enterprise global customer conference, June 8-11, 2015.
On last trading day Natus Medical Inc. (NASDAQ:BABY) moved up 0.50% to close at $38.08. Its volatility for the week is 3.48% while volatility for the month is 3.02%. BABY’s sales growth for past 5 years was 16.40% and its EPS growth for past 5 years was 20.10%. Natus Medical Inc. (NASDAQ:BABY) monthly performance is 2.81%. Natus Medical Inc. (BABY) is carrying a Zacks Rank #2.
EMC Corporation (NYSE:EMC) in last trading activity increased 0.51% to close at $25.81. Company weekly performance is -1.53% while its quarterly performance stands at -15.21%. EMC Corporation (NYSE:EMC) is -16.20% away from its 52 week high. EMC Corporation (NYSE:EMC) is planning to form a group of companies to lend a helping hand to customers by creating data lakes, with the help of its storage and VMware virtualization, besides Pivotal big-data smarts.
On last trading day CME Group Inc. (NASDAQ:CME) increased 0.55% to close at $94.79. Its volatility for the week is 1.76% while volatility for the month is 1.59%. CME’s sales growth for past 5 years was 3.60% and its EPS growth for past 5 years was 6.20%. CME Group Inc. (NASDAQ:CME) monthly performance is -1.29%. Under a CME Group Inc. (NASDAQ:CME) proposal being discussed with the U.S. Commodity Futures Trading Commission, the cash and securities put up by bank customers to back their derivatives wouldn’t have to be counted as the bank’s own assets, according to a person familiar with the matter, who asked not to be named because the talks are private.